Fangzhou Receives Gilead’s ‘Award of Excellence’ for AI-Powered Chronic Disease Management
SHANGHAI, Sept. 18, 2025 — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), an innovator in AI-powered online healthcare, was honored with the “Excellence Award” during Gilead Sciences, Inc.’s (“Gilead”) 2025 Multi-Channel Conference, held in Shanghai. Dr. Xie Fangmin, the Company’s Founder, Chairman, and CEO, participated in the event as a keynote speaker.
This accolade acknowledges Fangzhou’s accomplishments in propelling healthcare innovation and digitalization, highlighting its mutual dedication with Gilead to enhancing the provision of premium health services.
“Receiving this award validates our commitment to leveraging AI for improved chronic disease management,” Dr. Xie stated. “Through an expanded partnership with Gilead, our objective is to integrate advanced therapeutic approaches with our digital health proficiency to develop inventive, scalable patient care solutions.”
Fangzhou Honored with Gilead’s ‘Award of Excellence’ for AI-Powered Chronic Disease Management
Fangzhou and Gilead have maintained a strong collaborative relationship, focusing on domains including disease prevention, therapeutic interventions, and digital services for chronic conditions. Their respective missions—Gilead’s “creating a healthier world” and Fangzhou’s “better health for all”—are highly congruent in their pursuit of enhanced patient results.
At the roundtable discussion titled “Digital Power: Exploring New Models of Digital Health Education and Patient Management,” Dr. Xie presented his perspectives on the transformative impact of AI and digital technology on patient education and chronic disease care, proposing methods to boost both efficiency and reach.
The conference additionally featured the unveiling of Gilead’s industry-spanning program, “Together for Health: Building a New Ecosystem for Out-Patient Specialty Care,” which urged collaborators to elevate patient-focused services and fortify digitally-assisted care. Fangzhou, recognized as China’s foremost AI+ healthcare platform, endorsed this commitment, emphasizing its pivotal contribution to cultivating a unified, patient-centric healthcare environment.
Moving forward, Fangzhou intends to persistently utilize its AI capabilities and comprehensive chronic disease management offerings, simultaneously incorporating Gilead’s advanced knowledge in HIV, viral hepatitis, and oncology. This strategic integration aims to investigate novel “AI+ chronic care” frameworks and further public health initiatives.
About Gilead Sciences, Inc.
For over three decades, Gilead Sciences, Inc. has operated as a biopharmaceutical firm dedicated to discovering and delivering medical breakthroughs, with the ultimate vision of fostering a healthier global community. The corporation remains dedicated to pioneering advanced therapeutics for the prevention and treatment of severe illnesses such as HIV, viral hepatitis, COVID-19, cancer, and inflammatory conditions. Headquartered in Foster City, California, Gilead conducts operations in over 35 nations globally.
About Fangzhou Inc.
Fangzhou Inc. (06086.HK) stands as China’s premier digital platform for chronic disease management, catering to 52.8 million registered individuals and 229,000 medical practitioners as of June 30, 2025. The Company focuses on providing customized medical support and AI-driven precision medicine offerings. Further details are available at .
Media Contact
For additional questions or interview requests, kindly direct your correspondence to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
Disclaimer: This press statement includes forward-looking declarations. Actual outcomes could diverge substantially from projections owing to diverse circumstances. Readers are advised against excessive dependence on these assertions.
